TY - JOUR T1 - Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1098 LP - 1099 DO - 10.1136/annrheumdis-2021-220289 VL - 80 IS - 8 AU - Brian J Boyarsky AU - Jake A Ruddy AU - Caoilfhionn M Connolly AU - Michael T Ou AU - William A Werbel AU - Jacqueline M Garonzik-Wang AU - Dorry L Segev AU - Julie J Paik Y1 - 2021/08/01 UR - http://ard.bmj.com/content/80/8/1098.abstract N2 - The immune response to SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with rheumatic and musculoskeletal diseases (RMD) is undefined because these individuals were largely excluded from phase I–III studies. To better understand the immune response to vaccination in this patient population, we studied the antibody response in patients with RMD who completed the first dose of SARS-CoV-2 mRNA vaccination.Participants with RMD across the USA were recruited to participate in this prospective cohort via social media. Those with prior SARS-CoV-2 were excluded. We collected demographics, RMD diagnoses and immunomodulatory regimens and tested for SARS-CoV-2 antibodies at baseline and prior to the second vaccine dose. Antibody testing was conducted on the semiquantitative Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay (EIA) which tests for antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.1 We evaluated the association between demographic/clinical characteristics and positive antibody response using Fisher’s exact test and Wilcoxon rank-sum test.We studied 123 participants who received their first SARS-CoV-2 vaccination dose between 8 January 2021 and 12 February 2021; 52% underwent BNT162b2, and 48% underwent mRNA-1273 (table 1). The most common reported RMD diagnoses were inflammatory arthritis (28%), systemic lupus erythematosus (SLE) (20%), Sjogren’s syndrome (13%) and overlap connective tissue diseases(29%). … ER -